Substantial Evidence-Based Data Currently Being Generated by
Substantial Evidence-Based Data Currently Being Generated by 19 Ongoing Studies Using IceCure Medical's ProSense® Cryoablation System
IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that in parallel with the growing adoption of ProSense®, the number of independent, non-sponsored studies of its cryoablation system has significantly increased. In addition to the 12 studies already published in peer reviewed journals and presented in scienti
Related Keywords
China, Israel, United States, Israeli, Michael Polyviou, Todd Kehrli, Eyal Shamir, Icecure Medical Ltd, Nasdaq, Company Annual Report On Form, Cure Medical, Private Securities Litigation Reform Act, Middle East, Risk Factors, Annual Report, Erosense, Breast Cancer, Cosmetic Results, Musculoskeletal System, Tumor Removal, Independent Study, Benign Tumors, Kryoablation, Minimally Invasive,